Press Releases May 1, 2026 04:15 PM

Ready Capital Corporation Announces First Quarter 2026 Results and Webcast Call

Ready Capital Corporation schedules Q1 2026 earnings release and webcast call

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
RC

Ready Capital Corporation announced that it will release its first quarter 2026 financial results after the NYSE close on May 7, 2026. Management will host a webcast and conference call to discuss business updates and quarterly financials. The company specializes in providing loans backed by lower-to-middle-market commercial real estate and government-backed loans.

Ready Capital Corporation Announces First Quarter 2026 Results and Webcast Call
RC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Ready Capital will report Q1 2026 financial results on May 7, 2026, followed by a webcast and conference call for investors.
  • The company focuses on financing lower-to-middle-market commercial real estate loans including multifamily, investor, construction, and bridge loans, along with SBA and USDA guaranteed loans.
  • Ready Capital operates nationwide with over 400 professionals, concentrating on U.S.-based real estate finance and government-backed lending programs.

NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Ready Capital Corporation (NYSE: RC) (the “Company”) today announced that the Company will release its first quarter 2026 financial results after the New York Stock Exchange closes on Thursday, May 7, 2026. Management will host a webcast and conference call on Friday, May 8, 2026 at 8:30 a.m. Eastern Time to provide a general business update and discuss the financial results for the quarter ended March 31, 2026. 

Webcast:
The Company encourages use of the webcast due to potential extended wait times to access the conference call via dial-in. The webcast of the conference call will be available in the Investor Relations section of the Company’s website at www.readycapital.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register, download and install any necessary audio software.

Dial-in:
The conference call can be accessed by dialing 877-407-0792 (domestic) or 201-689-8263 (international).

Replay:
A replay of the call will also be available on the Company’s website approximately two hours after the live call through May 22, 2026.  To access the replay, dial 844-512-2921 (domestic) or 412-317-6671 (international). The replay pin number is 13759490.

About Ready Capital Corporation

Ready Capital Corporation (NYSE: RC) is a multi-strategy real estate finance company that originates, acquires, finances and services lower-to-middle-market investor and owner occupied commercial real estate loans. The Company specializes in loans backed by commercial real estate, including agency multifamily, investor, construction, and bridge as well as U.S. Small Business Administration loans under its Section 7(a) program and government guaranteed loans focused on the United States Department of Agriculture. Headquartered in New York, New York, the Company employs over 400 professionals nationwide.

Contact
Investor Relations
Ready Capital Corporation
212-257-4666
InvestorRelations@readycapital.com 


Risks

  • No specific operational or financial updates were provided, leading to uncertainty about quarterly performance impact on stock.
  • Potential market volatility impacting commercial real estate lending could affect the company’s loan portfolio and earnings.
  • Interest rate changes and economic conditions affecting real estate markets and small business lending programs pose ongoing risks.

More from Press Releases

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026